Marion Dorsch Sells 18,334 Shares of Blueprint Medicines Corporation (BPMC) Stock
Blueprint Medicines Corporation (NASDAQ:BPMC) insider Marion Dorsch sold 18,334 shares of Blueprint Medicines Corporation stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the sale, the insider now owns 18,334 shares of the company’s stock, valued at $1,199,960.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Blueprint Medicines Corporation (NASDAQ:BPMC) opened at $70.36 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28. Blueprint Medicines Corporation has a 1 year low of $25.08 and a 1 year high of $74.42.
Blueprint Medicines Corporation (NASDAQ:BPMC) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business’s quarterly revenue was up 31.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. equities analysts anticipate that Blueprint Medicines Corporation will post -3.74 EPS for the current year.
BPMC has been the subject of several research reports. Zacks Investment Research lowered Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. Canaccord Genuity reissued a “buy” rating and issued a $56.00 price objective on shares of Blueprint Medicines Corporation in a research note on Monday, September 11th. Wedbush reissued an “outperform” rating and issued a $82.00 price objective (up from $70.00) on shares of Blueprint Medicines Corporation in a research note on Monday, November 6th. DA Davidson assumed coverage on Blueprint Medicines Corporation in a research note on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. Finally, BidaskClub downgraded Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 19th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Blueprint Medicines Corporation presently has an average rating of “Buy” and a consensus price target of $70.47.
A number of hedge funds and other institutional investors have recently modified their holdings of BPMC. Rockefeller Financial Services Inc. bought a new position in Blueprint Medicines Corporation in the 3rd quarter worth approximately $160,000. Ameritas Investment Partners Inc. increased its position in Blueprint Medicines Corporation by 68.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,391 shares during the period. UBS Asset Management Americas Inc. bought a new position in Blueprint Medicines Corporation in the 1st quarter worth approximately $201,000. Fred Alger Management Inc. bought a new position in Blueprint Medicines Corporation in the 2nd quarter worth approximately $203,000. Finally, SG Americas Securities LLC increased its position in Blueprint Medicines Corporation by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after buying an additional 778 shares during the period. 91.99% of the stock is currently owned by institutional investors.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.